Gregory Bevels, MD
Family Medicine · Alexandria, LANPI 1750366027
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Lilly USA, LLC accounts for 83.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $21,954 and has fallen 99.0% since, to $228 in 2025. Among family medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $74.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$20K
- Novo Nordisk$597
- AstraZeneca$400
- GSK$345
- AbbVie$312
- Pfizer$230
- plus $2K from 32 others
What the payments were for
- Consulting fees$2,75012%
- Speaking & faculty fees$13,12555%
- Travel & lodging$3,28314%
- Food & beverage$4,56519%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,777 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 132 | $137,551 |
| MounjaroTirzepatide | 127 | $135,891 |
| JardianceEmpagliflozin | 142 | $114,092 |
| OzempicSemaglutide | 85 | $108,060 |
| FarxigaDapagliflozin Propanediol | 111 | $85,319 |
| RybelsusSemaglutide | 26 | $38,355 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $34,397 |
| XareltoRivaroxaban | 38 | $31,136 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $21,112 |
| EliquisApixaban | 35 | $20,632 |
| VascepaIcosapent Ethyl | 33 | $17,626 |
| LinzessLinaclotide | 28 | $17,362 |
| MyrbetriqMirabegron | 30 | $16,729 |
| JanuviaSitagliptin Phosphate | 19 | $14,343 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $14,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $19,872 | $273,442259 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $597 | $149,552123 claims |
| Boehringer IngelheimJardiance | $177 | $114,092142 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $400 | $95,132134 claims |
| GSKTrelegy Ellipta | $345 | $34,39733 claims |
| Johnson & JohnsonXarelto | $46 | $31,13638 claims |
| PfizerEliquis | $230 | $20,63235 claims |
| AbbVieLinzess | $312 | $17,36228 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $16,72930 claims |
| MerckJanuvia | $148 | $14,34319 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $187 | $11,31413 claims |
| NovartisEntresto | $31 | $10,39814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Alexandria
- Kenneth BrownAlexandria$17K
- Gregory BrianAlexandria$15K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
- Phillip ConnerSulphur$71K
- Richard JeansonneMandeville$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.